PepGen Inc. (PEPG) Form 8-K — Aug 6, 2026
PepGen reported a net loss of $17.8 million for the second quarter of 2026, with research and development expenses of $12.5 million. The company has a strong cash position of $117.2 million, sufficient to fund operations into the fourth quarter of 2027. The DSMB recommended advancing the Phase 2 FREEDOM2-DM1 study into the highest dose cohort of 12.5 mg/kg and escalating the open-label extension from 5 mg/kg to 10 mg/kg, citing a favorable safety profile.
Key figures
- Eps
- -0.26
- Revenue
- 0
- Net Income
- -17.8
- Cash Position
- 117.2
- Shares Outstanding
- 69.3
- Research And Development Expenses
- 12.5
- General And Administrative Expenses
- 6.4
Price after filing
1 day: +2.6%7 days: +54.4%30 days: +61.1%
Close on the filing date to close N calendar days later (from $1.93). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.